Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG

Next Previous
Trial Profile

Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indoximod (Primary) ; Cyclophosphamide; Etoposide; Lomustine; Temozolomide
  • Indications Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Medulloblastoma
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results of pooled analysis studying effect of indoximod-based chemo-immunotherapy((n=27, NCT02502708, NCT04049669) or (n=3, NCT05106296)) , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 19 Apr 2023 Results assessing whether immunotherapy designed to enhance immunogenic antigen-presentation during chemotherapy produces extensive reactivation of precursor T cells by selecting Informative patients from NCT04049669 and NCT05106296, presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 15 Jul 2022 Planned End Date changed from 2 Oct 2026 to 2 Oct 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top